A Nurse Practitioner's Perspective on OTC Analgesia

Over-the-counter (OTC) analgesics, including acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), are often an appropriate treatment option for patients experiencing mild to moderate pain. Certain OTC analgesics may exacerbate some coexisting conditions or interact with other medications patients are taking. Given the potential impact on patients, it is important to consider the following factors when making an OTC analgesic recommendation:

Considerations for NSAIDs

Coexisting medical conditions	NSAIDs have been reported to increase the risk of cardiovascular (CV) events, such as hypertension, stroke, congestive heart failure, and myocardial infarction. ^{1,2} Other potential effects include exacerbation of asthma, ³ increased risk of stomach bleeding, ⁴ and development of acute renal failure in patients with renal risk factors. ^{5,6}
Concomitant medications	Ibuprofen competes with aspirin in binding to the cyclooxygenase type 1 enzyme and can therefore reduce the cardioprotective effect of low-dose aspirin therapy. ⁷⁸
	Use of anticoagulants, steroids, or multiple NSAIDs may increase the risk of gastrointestinal (GI) events such as GI bleeding. ^{4,9,10}
	Olden estimate leave an increased viele of eastein NCAID acceptional dependent in a debut where a object of the
Other considerations	Older patients have an increased risk of certain NSAID-associated conditions, as mentioned above, such as CV events, stomach bleeding, and kidney disease. ^{4,6,11}
Other considerations	Older patients have an increased risk of certain NSAID-associated conditions, as mentioned above, such as CV events, stomach bleeding, and kidney disease. ^{4,6,11} Patients who consume 3 or more alcoholic beverages every day may be at increased risk for GI events when taking NSAIDs. ⁴
Other considerations	Older patients have an increased risk of certain NSAID-associated conditions, as mentioned above, such as CV events, stomach bleeding, and kidney disease. ^{46,11} Patients who consume 3 or more alcoholic beverages every day may be at increased risk for GI events when taking NSAIDs. ⁴

Considerations for acetaminophen	
Concomitant medications	Patients taking warfarin are advised to consult their healthcare professional before using acetaminophen, as this can increase the risk of bleeding. ⁴
Other considerations	Patients who consume 3 or more alcoholic beverages every day may be at risk for severe liver damage when taking acetaminophen. ⁴
Dosing	Exceeding the maximum recommended daily dose of 4000 mg poses a risk of liver damage and may occur when patients take OTC or prescription medications containing acetaminophen in addition to the recommended analgesic.

Counseling patients on their recommended OTC analgesic

It is important for patients to understand why a particular OTC analgesic was recommended and how the dose was individualized for them. Given the range of formulations of OTC products available to patients, it is necessary to clearly communicate the exact strength and dose of the recommended product. Counseling patients on the safe use of OTC analgesics can help them manage their pain both safely and effectively.

"When we recommend a product, we need to ensure that the patient understands the dosing we are recommending and why."



Contributor: Theresa Mallick-Searle, MS, RN-BC, ANP-BC Nurse Practitioner, Pain Management Stanford Health Care

> Get Relief Responsibly[®] Professional Resource Center GetReliefResponsiblyProfessional.com



A Nurse Practitioner's Perspective on OTC Analgesia

Over-the-counter (OTC) analgesics, including acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), are often an appropriate treatment option for patients experiencing mild to moderate pain. Certain OTC analgesics may exacerbate some coexisting conditions or interact with other medications patients are taking.

References

- 1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*. 2007;115(12):1634-1642.
- **2.** Bavry AA, Khaliq A, Gong Y, et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. *Am J Med.* 2011;124(7):614-620.
- 3. Peterson GM. Selecting nonprescription analgesics. Am J Ther. 2005;12(1):67-79.
- **4.** US Food and Drug Administration. Organ-specific warnings; internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final monograph. Final rule. *Fed Regist.* 2009;74(81):19385-19409.
- **5.** Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. *Expert Opin Drug Saf.* 2009;8(6):669-681.
- 6. Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs: proposed guidelines for monitoring toxicity. *West J Med.* 1991;155(1):39-42.
- 7. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med.* 2001;345(25):1809-1817.
- 8. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361(9357):573-574.
- **9.** Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*. 2008;118(18):1894-1909.
- **10.** García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. *Arthritis Res.* 2001;3(2):98-101.
- **11.** Barber JB, Gibson SJ. Treatment of chronic non-malignant pain in the elderly. *Drug Saf.* 2009;32(6):457-474.
- **12.** US Food and Drug Administration. Medication guide for nonsteroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/downloads/drugs/drugsafety/ucm387559.pdf. Revised May 2016. Accessed July 18, 2016.

"When we recommend a product, we need to ensure that the patient understands the dosing we are recommending and why."

